Sriram Sathy, PhD is the Chief Scientific Officer at AIRNA Biotechnology and a former CSO at Codiak Biosciences, with over 31 years of experience in genetic medicine, cancer biology, immunology, and neuroscience. He is an accomplished drug developer who has advanced numerous therapeutic candidates, including antibodies, engineered exosomes, and antisense oligonucleotides, from concept to clinical trials.
At Codiak, Dr Sathy led the preclinical evaluation of first-in-class engineered exosome therapeutic programs such as exoIL-12™, exoSTING™, and exoASO™-STAT6, which target cancers including cutaneous T-cell lymphoma and hepatocellular carcinoma. Prior to this, he served as Senior Director at Jounce Therapeutics, where he built translational platforms and biomarker strategies for immunotherapy programs like Vopratelimab. Earlier in his career at Merck Research Laboratories, he focused on translational oncology for biologics.
Dr Sathy earned his PhD in Molecular and Cell Biology from the Indian Institute of Science, Bangalore, and completed postdoctoral research at the University of Pennsylvania, focusing on the genetics of circadian rhythms. A prolific scientist, he has authored 32 peer-reviewed publications and holds multiple patents. Based in Lexington, MA, Dr. Sathy enjoys long-distance biking and is a passionate advocate for cancer research.